[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Colorectal Cancer: Epidemiology Forecast to 2028

November 2019 | 47 pages | ID: CEB1E279806CEN
GlobalData

US$ 3,995.00

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
Colorectal Cancer: Epidemiology Forecast to 2028

SUMMARY

Colorectal cancer (CRC) is a cancer that occurs in the large intestine or large bowel (Centers for Disease Control and Prevention, 2019). Most CRCs start as abnormal growths known as polyps on the inner lining of the colon or rectum. Over time, some polyps may turn into cancer (American Cancer Society, 2018). Common symptoms of CRC are: blood in stool, stomach pain, aches or cramps that do not go away, weight loss, and a persistent change in bowel habit. CRC screening tests help to find colorectal cancer at an early stage and/or remove pre-cancerous polyps in the colon or rectum (American Cancer Society, 2018).

GlobalData epidemiologists utilized country-specific cancer registries, national databases, and robust peer-reviewed journal articles to build the forecast for the diagnosed incident cases and diagnosed prevalent cases of CRC in the 8MM.

The following data describes epidemiology of CRC. GlobalData epidemiologists forecast an increase in the diagnosed incident cases of CRC in the 8MM, from 827,242 cases in 2018 to 1,078,959 cases in 2028 at an AGR of 3.04% during the forecast period. The diagnosed prevalent cases of CRC in the 8MM are also expected to increase, from 5,307,305 cases in 2018 to 7,303,381 cases in 2028, at an AGR of 3.76% over the forecast period. CRC is more common in men than women and the risk of developing CRC increases with age. These trends are reflected in GlobalData’s forecast for the diagnosed incident cases, with older age groups (ages ?65 years) contributing the highest proportion of the incident cases in the 8MM.

SCOPE
  • The Colorectal Cancer (CRC) Epidemiology Report and Model provide an overview of the risk factors and global trends of CRC in the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and China).
  • The report includes a 10-year epidemiological forecast for the diagnosed incident cases of CRC segmented by sex, and age (ages ?18 years) in these markets. - The diagnosed incident cases of CRC are further segmented by stage at diagnosis (stage I, II, III, and IV), by type of molecular markers (KRAS, NRAS, MET amplification, MSI-dMMR, HER2 amplification, NTRK gene fusion, and BRAF V600E), and sidedness (right-sided and left-sided). The report also includes diagnosed incident cases of CRC by population with curable synchronous liver metastases, five-year diagnosed prevalent cases of CRC, and all-time diagnosed prevalent cases of CRC.
    • The colorectal cancer epidemiology report and model were written and developed by Masters - and PhD-level epidemiologists.
  • The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.
  • The Epidemiology Model is easy to navigate, interactive with dashboards, and epidemiology-based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources.
REASONS TO BUY

The Colorectal Cancer Epidemiology series will allow you to -
  • Develop business strategies by understanding the trends shaping and driving the global colorectal cancer market.
  • Quantify patient populations in the global colorectal cancer market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for colorectal cancer therapeutics in each of the markets covered.
  • Understand magnitude of colorectal cancer population by stage at diagnosis.
1.1 List of Tables
1.2 List of Figures

2 COLORECTAL CANCER: EXECUTIVE SUMMARY

2.1 Related Reports
2.2 Upcoming Reports

3 EPIDEMIOLOGY

3.1 Disease Background
3.2 Risk Factors and Comorbidities
3.3 Global and Historical Trends
3.4 Forecast Methodology
  3.4.1 Sources
  3.4.2 Sources Not Used
  3.4.3 Forecast Assumptions and Methods
3.5 Epidemiological Forecast for CRC (2018-2028)
  3.5.1 Diagnosed Incident Cases of CRC
  3.5.2 Age-Specific Diagnosed Incident Cases of CRC
  3.5.3 Sex-Specific Diagnosed Incident Cases of CRC
  3.5.4 Diagnosed Incident Cases of CRC by Stage at Diagnosis
  3.5.5 Diagnosed Incident Cases of CRC by Molecular Markers
  3.5.6 Diagnosed Incident Cases of CRC by Population with Curable Synchronous Liver Metastasis
  3.5.7 Diagnosed Incident Cases of CRC by Sidedness
  3.5.8 Five-Year Diagnosed Prevalent Cases of CRC
  3.5.9 All-Time Diagnosed Prevalent Cases of CRC
3.6 Discussion
  3.6.1 Epidemiological Forecast Insight
  3.6.2 Limitations of Analysis
  3.6.3 Strengths of Analysis

4 APPENDIX

4.1 Bibliography
4.2 Primary Research - Prescriber Survey
4.3 About the Authors
  4.3.1 Epidemiologist
  4.3.2 Reviewers
  4.3.3 Global Director of Therapy Analysis and Epidemiology
  4.3.4 Global Head and EVP of Healthcare Operations and Strategy
4.4 About GlobalData
4.5 Contact Us
4.6 Disclaimer

LIST OF TABLES

Table 1: Risk Factors and Comorbid Conditions Associated with CRC
Table 2: 8MM, Diagnosed Incident Cases of CRC by Molecular Markers, N, Both Sexes, Ages ?18 Years, 2018
Table 3: High-Prescribing Physicians (Non-KOLs), Surveyed by Country, 2019

LIST OF FIGURES

Figure 1: 8MM, Diagnosed Incident Cases of CRC, N, Both Sexes, Ages ?18 Years, 2018 and 2028
Figure 2: 8MM, Diagnosed Prevalent Cases of CRC, N, Both Sexes, Ages ?18 Years, 2018 and 2028
Figure 3: 8MM, Diagnosed Incidence of CRC (Cases per 100,000 Population), Men, Ages ?18 Years, 2018-2028
Figure 4: 8MM, Diagnosed Incidence of CRC (Cases per 100,000 Population), Women, Ages ?18 Years, 2018-2028
Figure 5: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of CRC
Figure 6: 8MM, Sources Used to Forecast the Five-Year Diagnosed and Diagnosed Prevalent Cases of CRC
Figure 7: 8MM, Sources Used and Not Used to Forecast the Diagnosed Incident Cases of CRC by Stage at Diagnosis
Figure 8: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of CRC by Molecular Markers
Figure 9: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of CRC by Population with Curable Synchronous Liver Metastases
Figure 10: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of CRC by Sidedness
Figure 11: 8MM, Diagnosed Incident Cases of CRC, N, Both Sexes, ?18 Years, 2018
Figure 12: 8MM, Age-Specific Diagnosed Incident Cases of CRC, N, Both Sexes, Ages ?18 Years, 2018
Figure 13: 8MM, Sex-Specific Diagnosed Incident Cases of CRC, N, Ages ?18 Years, 2018
Figure 14: 8MM, Diagnosed Incident Cases of CRC by Stage at Diagnosis, N, Both Sexes, Ages ?18 Years, 2018
Figure 15: 8MM, Diagnosed Incident Cases of CRC by Population with Curable Synchronous Liver Metastasis, N, Both Sexes, Ages ?18 Years, 2018
Figure 16: 8MM, Diagnosed Incident Cases of CRC by Sidedness, N, Both Sexes, Ages ?18 Years, 2018
Figure 17: 8MM, Five-Year Diagnosed Prevalent Cases of CRC, N, Both Sexes, Ages ?18 Years, 2018
Figure 18: 8MM, Diagnosed Prevalent Cases of CRC, N, Both Sexes, Ages ?18 Years, 2018


More Publications